FDA Approves Mirdametinib for Adult and Paediatric Patients with NF1 Who Have Symptomatic Plexiform Neurofibromas Not Amenable to Complete Resection By Ogkologos - March 20, 2025 699 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the ReNeu study Source RELATED ARTICLESMORE FROM AUTHOR In Memory of Hernán Cortés-Funes: Former ESMO President and Pioneer in Medical Oncology Immune Pathways Help Identify Patients with Cancer and HIV Most Likely to Experience Reservoir Decay with Anti-PD1 Therapy Shaping Future Oncology Leaders: ESMO Broadens Its Career Development Opportunities MOST POPULAR Study Probes Awareness of Alcohol’s Link to Cancer January 18, 2023 ΟΡΘΟΚΟΛΙΚΟΣ ΚΑΡΚΙΝΟΣ February 7, 2019 Biosimilars for Cancer Emerge as Patents on Widely Used Biological Drugs... June 18, 2018 For Children with Retinoblastoma, Disparities Seen across the Globe March 12, 2020 Load more HOT NEWS Second Drug Targeting KRAS G12C Shows Benefit in Mutated Non-Small-Cell Lung... FDA Approves Sirolimus Protein-Bound Particles for Malignant Perivascular Epithelioid Cell Tumour 38% of Recurrent Breast Cancers Have a Different HER2 Status than... Finding Hope in the New Year During COVID-19 and Cancer
